Identification and characterization of eukaryotic initiation factor 5A‐2
Paul M. Clément(Universitair Ziekenhuis Leuven), Hans E. Johansson(Uppsala University), Zeljka Smit‐McBride(University of California, Davis), Edith C. Wolff(National Institutes of Health), Zandra A. Jenkins(University of Otago), Myung Hee Park(National Institutes of Health), John W.B. Hershey(Unknown), C. A. Henderson(University of California, Davis)
Cited by 125
Related Papers
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
|Journal of Clinical Oncology|2009|573
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
|The Lancet Oncology|2016|504
Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases
|The EMBO Journal|2004|461